Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01071239 · ClinicalTrials.gov registry record · Phase 2

Hematopoietic Stem Cell Transplant for Fanconi Anemia

A Phase 2 study of Fanconi Anemia, sponsored by Medical College of Wisconsin.

Completed
Registry status
Phase 2
Development phase
1
Enrollment target
1
Study location

NCT01071239: Completed Phase 2 study of Fanconi Anemia, sponsored by Medical College of Wisconsin.

NCT01071239 is a Phase 2 study of Fanconi Anemia that has completed, run by Medical College of Wisconsin. The registered enrollment target is 1 participants, below the 336-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01071239, a Phase 2 study of Fanconi Anemia, has completed, sponsored by Medical College of Wisconsin.

COMPLETED
Registry status
Phase 2
Development phase
1 participants
Enrollment target
1
Study location

Study Summary

The trial proposed is a single arm phase II treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and anti-thymocyte globulin (ATG- a non-chemotherapy drug whose role is to kill your immune system) for the treatment of patients with Fanconi anemia who have severe aplastic anemia (SAA), or myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), lacking HLA-genotypically identical donors using stem cell transplants derived from (1) HLA-compatible unrelated donors or (2) HLA haplotype-mismatched related donors.

Primary Outcome

To measure the incidence and quality of engraftment and hematopoietic reconstitution.

Conditions Studied

Fanconi Anemia

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG Busulfan
  • DRUG ATG
  • DEVICE CliniMACs device

Study Locations (1)

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2009-04
Est. Completion 2016-08-30
Phase Phase 2
Medical College of Wisconsin

447 total trials

What the finished NCT01071239 record still lists

NCT01071239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 336-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Fanconi Anemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT01071239 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01071239 about?

NCT01071239 is a clinical study titled "Hematopoietic Stem Cell Transplant for Fanconi Anemia". The trial proposed is a single arm phase II treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and anti-thymocyte globulin (ATG- a non...

What is the current status of trial NCT01071239?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2009-04. Estimated completion is 2016-08-30.

What conditions does trial NCT01071239 study?

This clinical trial studies the following conditions: Fanconi Anemia.

What interventions are being tested in trial NCT01071239?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Busulfan (DRUG), ATG (DRUG), CliniMACs device (DEVICE).

Who is sponsoring clinical trial NCT01071239?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01071239 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fanconi Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01071239's enrollment target sits among peer trials

1 16th of 15 the lowest of 15 other Fanconi Anemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fanconi Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01071239, the US trial registry maintained by the National Library of Medicine. NCT01071239 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.